Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma

被引:14
作者
Guiard, Emeline [1 ]
Clatot, Florian [2 ]
Even, Caroline [3 ]
Perreard, Marion [4 ]
Abdeddaim, Cyril [5 ]
Johnson, Alison [1 ]
Vauleon, Elodie [6 ]
Rambeau, Audrey [1 ]
机构
[1] Ctr Francois Baclesse, Med Oncol Dept, Caen, France
[2] Ctr Henri Becquerel, Med Oncol Dept, Rouen, France
[3] Inst Gustave Roussy, Head & Neck Med Oncol Dept, Villejuif, France
[4] Univ Hosp, Head & Neck Surg Dept, Caen, France
[5] Ctr Oscar Lambret, Med Oncol Dept, Lille, France
[6] Ctr Eugene Marquis, Med Oncol Dept, Rennes, France
关键词
Head and neck cancer; Nivolumab; Taxane; Immune checkpoint inhibitor; IMMUNE CHECKPOINT INHIBITORS; CHEMOTHERAPY PLUS CETUXIMAB; AND/OR METASTATIC HEAD; SALVAGE CHEMOTHERAPY; PROGNOSTIC-FACTORS; CLINICAL-OUTCOMES; CANCER PATIENTS; RECURRENT; PROGRESSION; THERAPIES;
D O I
10.1016/j.ejca.2021.09.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune checkpoint inhibitors are widely used in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). We aimed to describe response rates to taxanes after progression on nivolumab in R/M HNSCC patients. Methods: In this multicentric retrospective comparative study, we included patients treated with taxane monotherapy from 2014 to 2020. Patients were divided into two groups depending on whether they received nivolumab before taxanes (post-nivolumab group) or not (control group). The primary end-point was objective response rate (ORR) comparison between the two groups. The secondary end-points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and PFS ratio (PFSr=PFS associated with taxanes divided by PFS associated with the previous line of treatment), a survival marker used for comparison of different treatment lines. Results: Between July 2014 and August 2020, 185 patients were included (114 in the control group and 71 in the post-nivolumab group). ORR was significantly higher in the postnivolumab group (39.4% versus 26.3%, p = 0.03) as was DCR (69% versus 50%, P = 0.06). The median OS (7.5 months) and PFS (3.5 months) were not significantly different in the two groups, whereas PFSr was significantly improved in the post-nivolumab group (1.63 versus 1.11, P = 0.004). Conclusion: Response and DCRs with taxanes are improved after prior exposure to nivolumab. Thus, taxane monotherapy could be a good choice as third-line therapy after nivolumab following a platinum-based first line. These results currently apply to patients without access to or potential benefit from first-line pembrolizumab. (c) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:125 / 132
页数:8
相关论文
共 36 条
  • [1] Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck - An analysis of two Eastern Cooperative Oncology Group randomized trials
    Argiris, A
    Li, Y
    Forastiere, A
    [J]. CANCER, 2004, 101 (10) : 2222 - 2229
  • [2] Predictive resistance factors in lung cancer patients treated with Nivolumab. Retrospective study
    Bernichon, Emilie
    Tissot, Claire
    Bayle-Bleuez, Sophie
    Rivoirard, Romain
    Bouleftour, Wafa
    Forest, Fabien
    Tinquaut, Fabien
    Mery, Benoite
    Fournel, Pierre
    [J]. BULLETIN DU CANCER, 2021, 108 (03) : 250 - 265
  • [3] Billan S, 2020, LANCET ONCOL, V21, pE463, DOI 10.1016/S1470-2045(20)30328-4
  • [4] Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy
    Daste, Amaury
    De-Mones, Erwan
    Cochin, Valerie
    Dupin, Charles
    Digue, Laurence
    Ravaud, Alain
    Domblides, Charlotte
    [J]. ORAL ONCOLOGY, 2018, 81 : 116 - 118
  • [5] Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression
    Denaro, Nerina
    Merlano, Marco Carlo
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (03): : E42 - E47
  • [6] Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting
    Depenni, Roberta
    Rocca, Maria Cossu
    Ferrari, Daris
    Azzarello, Giuseppe
    Baldessari, Cinzia
    Alu, Massimiliano
    Nole, Franco
    Codeca, Carla
    Boscolo, Giorgia
    Piccininni, Marco
    Cavalieri, Stefano
    Bossi, Paolo
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 115 : 4 - 12
  • [7] Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
    Desnoyer, Aude
    Broutin, Sophie
    Delahousse, Julia
    Maritaz, Christophe
    Blondel, Louis
    Mir, Olivier
    Chaput, Nathalie
    Paci, Angelo
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 128 : 119 - 128
  • [8] Distant metastases in head and neck cancer
    Duprez, Frederic
    Berwouts, Dieter
    De Neve, Wilfried
    Bonte, Katrien
    Boterberg, Tom
    Deron, Philippe
    Huvenne, Wouter
    Rottey, Sylvie
    Mareel, Marc
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (09): : 1733 - 1743
  • [9] Forastiere AA, 1998, CANCER, V82, P2270, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.3.CO
  • [10] 2-Q